[1]刘春兴.上海地区胃蛋白酶原参考值的建立及临床应用[J].现代检验医学杂志,2015,30(01):121-122.[doi:10.3969/j.issn.1671-7414.2015.01.035]
　LIU Chun-xing.Establishment of Pepsinogen Reference Range and Its Clinical Application in Shanghai Area[J].Journal of Modern Laboratory Medicine,2015,30(01):121-122.[doi:10.3969/j.issn.1671-7414.2015.01.035]
点击复制

上海地区胃蛋白酶原参考值的建立及临床应用()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年01期
页码:
121-122
栏目:
研究简报·实验技术
出版日期:
2015-01-30

文章信息/Info

Title:
Establishment of Pepsinogen Reference Range and Its Clinical Application in Shanghai Area
文章编号:
1671-7414(2015)01-121-03
作者:
刘春兴
华东疗养院检验科,江苏无锡 214065
Author(s):
LIU Chun-xing
Department of Clinical Laboratory,Huadong Sanatorium,Jangsu Wuxi 214065,China
关键词:
乳胶增强免疫比浊法;  胃蛋白酶原;  参考范围
分类号:
R446.112
DOI:
10.3969/j.issn.1671-7414.2015.01.035
文献标志码:
A
摘要:
目的 建立乳胶增强比浊法测定上海地区健康人群血清胃蛋白酶原(pepsinogen,PG)的参考范围并探讨其在胃病的临床应用价值。方法 随机抽取8 763例居住上海市10年以上的健康成年人和经胃镜及病理证实的269例不同胃病患者,采用乳胶增强免疫比浊法检测血清胃蛋白酶原Ⅰ(PGⅠ)和胃蛋白酶原Ⅱ(PGⅡ)含量。结果 血清PGⅠ,PGⅡ及PGⅠ/PGⅡ比值(PGR)呈偏态分布,PGⅠ,PGⅡ和PGR的95%参考区间分别为24.6～98.97 ng/ml,≤21.7 ng/ml和≥3.43。萎缩性胃炎组和胃癌组的PGⅠ分别是36.6 ng/ml(P=0.007),20.6 ng/ml(P<0.001); PGR分别是3.63,3.2(P<0.001),水平显著降低; 消化性溃疡组PGⅠ是83.6 ng/ml(P<0.001),PGⅡ是17.5 ng/ml(P<0.001),明显升高,PGR是4.37(P=0.006),水平显著降低。结论 建立乳胶增强免疫比浊法检测上海地区正常人群胃蛋白酶原的参考范围,有助于临床更好地应用于胃疾病的诊断。
Abstract:
Objective To establish serum pepsinogen(PG)reference range healthy crowd with latex-enhanced immunoturbidimetry of and explore its clinical application in stomach disease in Shanghai area.Methods Selected randomly 8 763 healthy adults who livied in Shanghai for more than 10 years and 269 patients with different stomach trouble confirmedby gastroscope and pathology.By latex-enhanced immunoturbidimetry to detect the serum pepsinogen Ⅰ(PGⅠ)and pepsinogen Ⅱ(PGⅡ).Results The serum PGⅠ,PGⅡand PGⅠ/PGⅡlevel showed a skew distribution.The normal reference range was 24.6～98.97 ng/ml,≤21.7 ng/ml and ≥3.43.PGⅠandPGR values decreased significantly in both atrophic gastritis(PGⅠ=36.6 ng/ml,P=0.007,PGR=3.63,P<0.001)and gastric cancer groups(PGⅠ=20.6 ng/ml,PGR=3.2,P<0.001).PGⅠand PGⅡvalues increased significantly in digestive ulcer group(PGⅠ=83.6 ng/ml,PGⅡ=17.5 ng/ml,P<0.001),but PGR values decreased significantly(PGR=4.37,P=0.006).Conclusion Establishing serum pepsinogen reference range of healthy crowd with latex-enhanced immunoturbidimetry in the Shanghai area can help to diagnose betterthe stomach trouble.

参考文献/References:

[1] 张 愔,吴银萍,侯龙敏.血清胃蛋白酶原检测在胃肠疾病诊断中的意义[J].医药论坛杂志,2007,28(5):92-93.Zhang Y,Wu YP,Hou LM.Serum pepsinogen detection in the diagnosis of gastrointestinal diseases[J].Journal of Medical Forum,2007,28(5):92-93.
[2] 孟凡斌,吴明守.胃蛋白酶原法筛检胃癌[J].日本医学介绍,2006,27(1):36-37. Meng FB,Wu MS.Pepsinogen method of screening for gastric cancer[J].Progress in Japanese Medicine,2006,27(1):36-37.
[3] 周红凤,刘 丹,吴 瑾,等.胃蛋白酶原和胃癌相关抗原与胃癌的研究进展[J].世界华人消化杂志,2007,15(17):1940-1946. Zhou HF,Liu D,Wu J,et al.A review of advances related to pepsinogen and MG7Ag in gastric cancer[J].World Chinese Journal of Digestology,2007,15(17):1940-1946.
[4] 曹 勤,冉志华,箫树东.血清胃蛋白酶原、胃泌素-17和幽门螺杆菌IgG抗体筛查萎缩性胃炎和胃癌[J].胃肠病学,2006,11(7):388-394. Cao Q,Ran ZH,Xiao SD.Screening of a trophic gastritis and gastric cancer using serum pepsinogen,gastrin-17 and helicobacterpylori IgG antibodies[J].Chinese Journal of Gastroenterology,2006,11(7):388-394.
[5] 刘中娟,程歆琦,郭子建,等.胃癌癌前病变相关标志物的检测[J].国际肿瘤学杂志,2013,40(2):134-137. Liu ZJ,Cheng XQ,Guo ZJ,et al.Detection of the tumor markers in patients with gastric precancerous lesions[J].Journal of International Oncology,2013,40(2):134-137.
[6] 朱 岚,黄 飚,张 珏,等.不同人群胃蛋白酶原水平检测分析[J].中国公共卫生,2009,25(10):1216-1217. Zhu L, Huang B, Zhang J,et al.Serum pepsinogen level in health persons and patients with chronic gastric disease or stomach cancer[J].ChineseJournal of Public Health,2009,25(10):1216-1217.
[7] 孙丽萍,宫月华,王 兰,等.辽宁庄河地区居民血清胃蛋白酶原含量检测分析[J].中华消化杂志,2006,26(10):649-653. Sun LP,Gong YH,Wang L,et al.Serum pepsinogen I and Ⅱ in residents from Zhuanghe county in North China[J].Chinese Journal of Digestion,2006,26(10):649-653.
[8] Osishi Y, Kiyohara Y, Kubo M,et al.The serum pepsinogen test as a predictor of gastric cancer:the Hisayama study[J].American Journal of Epidemiology,2006,163(7):629-637.
[9] Ghoshal UC,Kumar S,Krishnani N.et al.Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen I,pepsinogenⅡ and gastrin-17 levels in a low incidence area of gastric cancer endemic for H.pyloriinfection[J].Trop Gastroenterol,2011,32(4):292-298.
[10] Kikuchi R,Abe Y,Iijima K,et al.Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk ofearly gastric cancer[J].Tohoku J Exp Med,2011,223(1):35-44.

相似文献/References:

[1]张培莉,刘义庆,张炳昌,等.体检人群血清胃蛋白酶原、胃泌素-17与幽门螺杆菌抗体分型检测临床分析[J].现代检验医学杂志,2017,32(04):32.[doi:10.3969/j.issn.1671-7414.2017.04.009]
　ZHANG Pei-li,LIU Yi-qing,ZHANG Bing-chang,et al.Clinical Analysis of Serum Pepsinogen,Gastrin-17 and Helicobacter Pylori Antibody Typing in Physical Examination[J].Journal of Modern Laboratory Medicine,2017,32(01):32.[doi:10.3969/j.issn.1671-7414.2017.04.009]

备注/Memo

备注/Memo:

作者简介:刘春兴,男,在读研究生,E-mail:znso4liu@163.com。
更新日期/Last Update: 2015-01-30